GBT440-031 Sickle Cell Disease

Sickle Cell

Protocol:GBT440-031

Condition or Disease: Sickle Cell Disease

Study Type: Interventional (Clinical Trial)

Status: Enrollment Paused

Study Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Subjects with Sickle Cell Disease

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03036813

Share This Post

Explore More News

Blog

Rare Disease Advisory Council seeks input for healthier Nevada

The Rare Disease Advisory Council is seeking input from the public to help improve the health of Nevada residents. The council is focused on addressing the needs of those with rare diseases and is looking for feedback from patients, caregivers, and healthcare providers. The goal is to gather information that can be used to develop strategies and policies to improve the lives of those affected by rare diseases in Nevada.

Blog

Cure 4 The Kids Foundation Announces Senior Leadership Changes

Cure 4 The Kids Foundation is pleased to announce the appointment of Christine Tonn as its new chief executive officer (CEO), effective January 1, 2024. This promotion is part of a board of directors-supported management succession plan.